Bayer Suffers Nexavar Setback As India's Supreme Court Dismisses Linkage of Patent With Generic Marketing Approval
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - German pharma and healthcare firm Bayer suffered yet another jolt in its two-year attempt to establish a patent linkage to registration of generic versions of its kidney and liver cancer drug Nexavar (sorafenib) as India's Supreme Court dismissed the company's pleas and referred the case back to the Delhi High Court
You may also be interested in...
Bayer Challenges Nexavar Compulsory License To Natco; Says It Endangers Pharma Research
The German firm says challenges faced by the Indian healthcare system has little or nothing to do with patents
Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
MUMBAI - In a move that could have far-reaching impact in determining India's approach to compulsory licensing, Natco Pharma - the local oncology and anti-HIV drugs specialist - has written to German drugs-to-agrochemicals giant Bayer to provide it with a "voluntary license" to manufacture and market its anti-cancer drug brand Nexavar (sorafenib)
Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
MUMBAI - In a move that could have far-reaching impact in determining India's approach to compulsory licensing, Natco Pharma - the local oncology and anti-HIV drugs specialist - has written to German drugs-to-agrochemicals giant Bayer to provide it with a "voluntary license" to manufacture and market its anti-cancer drug brand Nexavar (sorafenib)